Abstracts

INVESTIGATING THE EFFECT OF THERAPEUTICS ON THE MICROBIOME OF PATIENTS WITH HIV/AIDS

Here, we investigate the pathways by which maraviroc-treated cohorts experience improved mucosal immunity through changes in host:microbial interactions. We hypothesize that maraviroc therapy-induced improvements in mucosal immunity impacts the microbial mucosal interaction through either a change in the distribution of the microbial communities, their metabolic state, or both. We previously performed a three-arm, randomized clinical…

TLR9 AGONIST MODULATED INTESTINAL GLYCOGENE EXPRESSION IMPACTS MICROBIOME DIVERSITY

An emerging paradigm suggests that the gut-associated glycome is critical to the maintenance of a homeostatic relationship between the host and its gut microbiota. In HIV infection, alterations in glycan metabolism may contribute to HIV-mediated intestinal damage, microbial translocation, and chronic inflammation. Given that we recently found that the TLR9 agonist lefitolimod (MGN1703, Mologen AG)…

HIV-ASSOCIATED CHANGES OF THE GUT MICROBIOME IN ARV-TREATED, UNTREATED, & CONTROLLERS

HIV infection is associated with gut microbiome alterations, enteropathy, and intestinal translocation of microbial products. It is unclear what HIV associated changes in the gut microbiome occur in HIV-infected individuals who control the disease immunologically without treatment, but they provide a unique model to investigate the effects of HIV infection. Our Boston cohort (n=183), the…

COMPLEXITIES OF GUT MICROBIOME DYSBIOSIS IN HIV INFECTED AND HIGH RISK POPULATIONS

Gut microbiome composition in HIV-infected populations has been shown by our lab and others to be significantly different from that of HIV negative individuals, even with effective Antiretrovoral Therapy (ART). However, understanding compositional changes associated specifically with HIV infection and immune dysfunction is hindered by several confounding factors including factors unrelated to HIV disease itself…

MOLECULAR DETERMINANTS OF HIV HYPERMUTATION

The human genome encodes seven APOBEC3 (A3) enzymes, at least four of which (A3D, A3F, A3G, and A3H) can induce G-to-A mutations in HIV-1 genomes. These enzymes leave two distinct hypermutation signatures: GG-to-AG and GA-to-AA. The former signature is dominant in viral sequences hypermutated in vitro by A3G, whereas the latter is prevalent in sequences…

INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS

HIV infection is accompanied by high levels of inflammation that predict increased mortality in adults. HIV-exposed uninfected (HEU) infants also have increased infectious morbidity and mortality, but little is known about their levels of inflammation and immune activation. In this study, we assessed how inflammatory and monocyte activation markers correlated between mothers and HEUs at…

INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA

HIV-exposed uninfected (HEU) infants continue to experience increased morbidity/mortality from infectious causes compared with infants born to HIV-uninfected women. To explore possible immune etiologies, we conducted an immune profiles analysis, comparing profiles from a Botswana-based cohort of HEU to HIV-unexposed (HU) infants. Multiparametric flow cytometry was used to quantify proportions and phenotypic characteristics of innate…

MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS

The MITABS study (Microbial Translocation[MT], Immune Activation[IA], and Altered Bowel Flora Study[ABS]) is the first prospective, longitudinal study designed to simultaneously assess MT, IA, and alterations in the gut microbiome with clinical events in young (enrolled at < 6 months) HIV perinatally infected (HEI); and perinatally exposed, uninfected(HEU) infants in the Dominican Republic (DR) before…